What is Leerink Partnrs’ Estimate for TNYA FY2025 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Research analysts at Leerink Partnrs reduced their FY2025 earnings estimates for Tenaya Therapeutics in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.71) for the year, down from their prior forecast of ($0.70). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.06.

A number of other research firms also recently weighed in on TNYA. Wall Street Zen raised shares of Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Finally, Chardan Capital restated a “buy” rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.25.

Tenaya Therapeutics Price Performance

Shares of Tenaya Therapeutics stock opened at $0.67 on Monday. The firm has a market cap of $109.02 million, a PE ratio of -0.70 and a beta of 3.01. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $4.01. The company has a 50 day simple moving average of $0.67 and a two-hundred day simple moving average of $0.67.

Institutional Trading of Tenaya Therapeutics

Several large investors have recently added to or reduced their stakes in TNYA. Savant Capital LLC acquired a new position in Tenaya Therapeutics during the 2nd quarter worth about $52,000. CWM LLC raised its position in shares of Tenaya Therapeutics by 25.2% during the 2nd quarter. CWM LLC now owns 90,087 shares of the company’s stock worth $55,000 after acquiring an additional 18,142 shares in the last quarter. Woodline Partners LP raised its position in shares of Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock worth $3,373,000 after acquiring an additional 5,896,873 shares in the last quarter. AQR Capital Management LLC purchased a new position in Tenaya Therapeutics during the 1st quarter worth approximately $442,000. Finally, DAFNA Capital Management LLC purchased a new position in Tenaya Therapeutics during the 1st quarter worth approximately $27,000. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.